192 results
Page 4 of 10
8-K
EX-99.1
a39g zp7w99jy3io
1 Mar 22
Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors
8:35am
8-K
EX-99.1
q9if4 jalq1
14 Feb 22
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
9:00am
8-K
EX-99.1
t94 1ff83gds
18 Jan 22
Regulation FD Disclosure
8:30am
8-K
EX-10.1
u8uly 13skta
27 Dec 21
Entry into a Material Definitive Agreement
8:06am
8-K
EX-10.2
2ap 0wt0lzt
27 Dec 21
Entry into a Material Definitive Agreement
8:06am
8-K
EX-99.1
0eq0 yel7dkxrj2
27 Dec 21
Entry into a Material Definitive Agreement
8:06am
8-K
EX-99.1
g94h4f7wbt
1 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
1oneyw8it 9ipo1g
12 Nov 21
Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
7:30am
8-K
EX-99.1
4seuoenk3r o8x6o1lvl
19 Oct 21
Regulation FD Disclosure
9:00am
8-K
EX-99.1
8bualu
18 Oct 21
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
8:25am
8-K
EX-99.1
g4pmh5
12 Aug 21
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
8:09am
8-K
EX-99.1
cc2z2w5a bv3hlahy
13 Jul 21
Regulation FD Disclosure
8:35am
8-K
EX-1.1
esrw7
25 Jun 21
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-10.1
8jq3l06rs2
25 Jun 21
Entry into a Material Definitive Agreement
5:22pm